Company / Cash & Equivalents
Glaukos Corp. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$90.8M
FY2025
5-year range
$90.8M / $169.6M
FY2021-FY2025
Trend
-46.5%
vs FY2024
Sector context
#116 of 152
Health Care
What the data says
Glaukos Corp.'s cash & equivalents of $91M is lower than 76% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $6M in FY2016 to $170M in FY2024.
Based on SEC 10-K filings.
$91M in FY2025 with a 5-year CAGR of -1.2%.
Declined from $93M to $91M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -8.8%
- 5-Year CAGR
- -1.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 152This company $90.8M Sector average $1.2B
▼
-92.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 46.5% year-over-year.
- Ranks #116 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $90.8M | -46.5% |
| FY2024 | $169.6M | +81.5% |
| FY2023 | $93.5M | -21.8% |
| FY2022 | $119.5M | +18.7% |
| FY2021 | $100.7M | +4.3% |
| FY2020 | $96.6M | +54.7% |
| FY2019 | $62.4M | +109.3% |
| FY2018 | $29.8M | +21.7% |
| FY2017 | $24.5M | +277.4% |
| FY2016 | $6.5M | -69.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026